Capricor Therapeutics Stock (NASDAQ:CAPR)

Forecast Ownership Financials Chart Transcripts

Previous Close

$3.85

52W Range

$2.96 - $40.37

50D Avg

$19.61

200D Avg

$23.20

Market Cap

$226.02M

Avg Vol (3M)

$2.82M

Beta

0.53

Div Yield

CAPR Company Profile

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

231

IPO Date

Feb 13, 2007

Website

CAPR Performance

CAPR Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$22.27M	$25.18M
Operating Income	$-108.14M	$-42.56M	$-24.08M
Net Income	$-105.04M	$-40.47M	$-22.29M
EBITDA	$-108.14M	$-41.14M	$-23.01M
Basic EPS	$-2.26	$-1.15	$-0.83
Diluted EPS	$-2.26	$-1.15	$-0.83

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 12, 26 | 4:30 PM

Q4 25Mar 12, 26 | 4:30 PM

Q3 25Nov 10, 25 | 4:30 PM

Peer Comparison

Ticker	Company
ARCT	Arcturus Therapeutics Holdings Inc.
LXEO	Lexeo Therapeutics, Inc. Common Stock
EDIT	Editas Medicine, Inc.
PRQR	ProQR Therapeutics N.V.
ALLO	Allogene Therapeutics, Inc.
CABA	Cabaletta Bio, Inc.
VNDA	Vanda Pharmaceuticals Inc.
ACHV	Achieve Life Sciences, Inc.
TRDA	Entrada Therapeutics, Inc.
IMMP	Immutep Limited